Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy

Eur J Cancer. 2018 Nov:103:284-286. doi: 10.1016/j.ejca.2018.08.022. Epub 2018 Sep 26.

Authors

Luigia Panariello¹, Davide Fattore², Maria Carmela Annunziata¹, Francovito Piantedosi³, Marina Gilli³, Gabriella Fabbrocini¹

Affiliations

¹ Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
² Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Electronic address: dott.davidefattore@gmail.com.
³ Department of Pulmonary Oncology, AORN Ospedale Dei Colli, Naples, Italy.

PMID: 30268391
DOI: 10.1016/j.ejca.2018.08.022

No abstract available

Keywords: Anti–PD-1; Bullous pemphigoid; Nivolumab.

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use*
Humans
Male
Medical Oncology
Middle Aged
Nivolumab / pharmacology
Nivolumab / therapeutic use*
Pemphigoid, Bullous / drug therapy*
Pemphigoid, Bullous / pathology

Substances

Antineoplastic Agents, Immunological
Nivolumab